OTLK · Outlook Therapeutics, Inc.

This 8-K discloses a complex, multi-tranche financing event combining a registered direct offering with a concurrent private placement and warrant amendment — all closing on April 23, 2026. The core transaction involved the issuance of 16.13 million shares of common stock at $0.31 per share, yielding ~$5.0 million in gross proceeds before fees. Critically, each share was paired with a Common Warrant exercisable at the same $0.31 price, but subject to two material conditions: (i) stockholder approval of the warrant share issuance and (ii) an amendment to the certificate of incorporation increasing authorized shares — both of which the company has committed to pursue within 90 days. This structure defers immediate dilution from warrant exercises but creates near-term governance and capital market risk around the upcoming shareholder vote. Simultaneously, the company issued 1.13 million Placement Agent Warrants (7% of shares sold) at a 25% premium ($0.3875), introducing a layered incentive mechanism where the placement agent earns additional warrants upon cash exercises of the Common Warrants. Most significantly, the company amended 2.14 million pre-existing warrants — originally issued in January 2025 at $2.26 — slashing the exercise price to $0.31. This unilateral reduction dramatically increases the likelihood of near-term exercise, converting previously out-of-the-money instruments into immediately in-the-money claims, thereby accelerating potential dilution and reducing future funding optionality. The aggregate effect is a substantial, front-loaded equity overhang: over 19.4 million new or repriced warrant securities now exist alongside the newly issued shares, all tied to a single financing round. Given the company’s small market capitalization and prior financial disclosures indicating limited cash runway, this event represents a pivotal capital markets milestone with high implications for ownership dilution, voting control, and future financing flexibility.